3 tracked superinvestors hold Incyte Corp. (INCY), worth $1.4B combined, led by Team. Smart money is accumulating INCY as of the latest 13F filings.
Current price
$126.75
+48.3%
1Y
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase…
Market cap
$19.4B
P/E
13.69
Div yield
0.0%
Revenue YoY
21.2%
Analyst target
$130
Snapshot for context. For deep analysis use a stock screener — this page is about who owns it.
Superinvestors holding
3
tracked 13F / N-PORT funds
Combined value
$1.4B
disclosed long exposure
Tier-1 conviction
0
concentrated holders
Net this quarter
+1
1 buying · 0 selling
Smart money is net accumulating INCY: 1 funds added or opened versus 0 trimming.
Incyte Corp. (INCY) appears mainly in diversified and quant books here (3 funds, $1.4B combined) rather than in concentrated conviction portfolios — read the holders below with that in mind.
The largest position belongs to Team at 0.8% of their book — no single tracked manager treats it as an outsized, top-weighted bet.
No tracked fund opened a new position this quarter; 1 added and 0 trimmed, a net add.
| Investor | Move | % of their portfolio | Position value |
|---|---|---|---|
| Held | 0.8% | $902M | |
| Held | 0.6% | $398M | |
| Added | 0.2% | $82M |
Tier badge = signal quality: 1 concentrated conviction · 2 quant/multi (context) · 3 retail & diversified. Only Tier 1 holdings feed the consensus signal.
3 insiders filed SEC Form 144 for $15M of proposed sales in the last 90 days. A 144 is filed before the trade — see who else is selling.
| Insider | Role | Shares | Value | Filed |
|---|---|---|---|---|
| Pablo Cagnoni | Officer | 10,801 | $1M | 2026-08-19 |
| Pablo Cagnoni | Officer | 10,803 | $1M | 2026-08-12 |
| Pablo Cagnoni | Officer | 10,640 | $1M | 2026-08-05 |
| Patrick A Mayes | Officer | 6,055 | $729K | 2026-08-03 |
| Patrick A Mayes | Officer | 41,899 | $5M | 2026-07-31 |
| Pablo Cagnoni | Officer | 15,888 | $2M | 2026-07-31 |
| Steven Stein | Officer | 28,237 | $3M | 2026-07-15 |
Which superinvestors own INCY?
3 tracked funds hold Incyte Corp. (INCY), the largest being Team (Dodge & Cox Stock) at 0.8% of its 13F portfolio. 0 of them are concentrated Tier-1 conviction managers.
Is smart money buying or selling INCY?
In the most recent 13F quarter, 1 tracked fund added or opened INCY and 0 trimmed it.
How much INCY do tracked funds hold?
Combined disclosed long exposure to INCY across tracked superinvestors is $1.4B as of the Jun 2026 filings.
One email when a tracked manager opens, adds to or files to sell a position — from Form 4, 13D and Form 144, not the 45-day-old 13F.
Holdings aggregated from the latest SEC 13F & N-PORT filings via FMP · Jun 2026 quarter. Long equity positions only, reported with up to a 45-day delay — for activity between filings see real-time moves. Not financial advice.